Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 365 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR New on NCI’s Websites for December 2023 December 28, 2023 Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... February 18, 2025 DIY Mosquito Traps & Deterrents (That Really Work) June 23, 2021 EMA Recommends Granting a Marketing Authorisation for Elinzanetant September 26, 2025 Load more HOT NEWS PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer Teen Helps Mom With Cancer Shave Her Head, Then Turns To... Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer... Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle
